Schlieren ZH – Kuros Biosciences has received approval in the USA for the use of MagnetOs Flex Matrix in the interbody region. This means that the bone substitute can be used in all spinal implants.
Schlieren-based Kuros Biosciences AG has received approval from the US Food and Drug Administration(FDA) for the use of MagnetOs Flex Matrix in the interbody region. According to the press release , MagnetOs Flex Matrix can now be used in any interbody space such as the cervical spine, thoracic spine or lumbar spine and in any cage that is approved for use with a bone graft substitute. A cage serves as a spacer in the spine instead of a no longer functioning intervertebral disc.
Interbody cages are used in nearly half of the estimated 1.5 million instrumented spinal fusions performed annually in the U.S., according to Kuros. MagnetOs Flex Matrix is particularly suitable for interbody applications as it remains stable and flexible even when wet due to its excellent granule retention and can therefore be introduced either via a funnel or directly into a cage of any size.
"This is an important milestone for our company and for the surgical community. With this clearance, we have a significant opportunity to re-engage surgeons who were previously unable to use our MagnetOs Flex Matrix product for interbody procedures," Chris Fair, CEO of Kuros, is quoted as saying.
Kuros Biosciences AG is a spin-off from the University of Zurich(UZH) and the Swiss Federal Institute of Technology Zurich(ETH). The company is based in the Bio-Technopark Schlieren-Zurich. ce/gba